Danchen Wu

Danchen Wu is a Postdoctoral Fellow and Adjunct Assistant Professor in the Department of Medicine at Queen's University, affiliated with the School of Medicine within the Faculty of Health Sciences. He holds a PhD (2015) and MD (2012) from Tongji University.

His research focuses on mitochondrial biology, pulmonary hypertension, and cardiorespiratory medicine, with particular emphasis on mitochondrial fission dynamics, hypoxia signaling, and epigenetic regulation in disease mechanisms. Current work explores how mitochondrial dysfunction contributes to cell cycle dysregulation, right ventricular failure, and cancer-like phenotypes in pulmonary arterial hypertension (PAH).

Key research areas include dynamin 2 regulation, NLRP3 inflammasome activation, and mitochondrial metabolic shifts in fibroblast behavior. His studies also investigate therapeutic strategies targeting mitochondrial fission inhibitors like drpitor1a for PAH and ischemia-reperfusion injury.

Recent publications highlight discoveries in oxygen sensing via mitochondrial complex I, epigenetic drivers of PAH, and the role of protein O-GlcNAcylation in cardiac dysfunction. Collaborative research extends to translational studies involving preclinical drug efficacy testing and biomarker identification for PAH prognosis.